Gilead Sciences, Inc. (NASDAQ:GILD) has an investor that is more than willing to trust it completely. This can be analysed from the fact that BB&T Securities LLC recently increased its stake in the company by as much as 17.4% in Q3. This firm has 718,792 shares in company’s stock, after its recent purchase of 106,530 shares. Gilead Sciences, Inc. has an investment portfolio that is composed of 0.8% of BB&T Securities LLC.
Other investors too raised share in the company
Apart from the firm mentioned above, Tarbox Group Inc. too, raised its stake in the company by as much as 0.4% in Q3. It has 6,522 shares in the biopharmaceutical company now. Meanwhile, Birch Hill Investment Advisors LLC raised its stake in the company by 0.9% in Q2. It has 3,336 shares in the stock now. West Oak Capital LLC raised the position with an increase by 0.7% in Q3. The firm owns 4,449 shares in all now.
Among other prime investors who have raised their stake in the company, some of them include Alpha Windward LLC and Albion Financial Group UT.
Increased trust in the biopharmaceutical company
The increased trust of the investors, of late, can be attributed to commercialization, development and discovery of some of the diseases, for which, there is a need for specific kinds of treatments. These diseases include HIV, Hepatitis C and chronic hepatitis B virus infections. Other diseases that the company focuses upon include inflammation/respiratory, cardiovascular, hematology/oncology and human immunodeficiency virus (HIV), apart from the liver infections of different kinds.
It is important to note that the investors, who have increased their stake in the company, are now looking for this company to make successful clinical researches that can enhance the company’s revenue targets. For any investor, the long term growth of a company is more valuable than the short term targets, which would exactly be the scenario here.